文献速递帕金森病与运动障碍

行为疗法对比药物治疗帕金森病膀胱过度活动症:随机非劣效性试验

Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease: A Randomized Noninferiority Trial.
PubMed 文献 · JAMA Neurol · 2025-01-01

该12周随机非劣效性试验纳入77例帕金森病伴膀胱过度活动症患者,比较护士主导的盆底肌训练行为疗法与索利那新药物治疗。

要点

  • 行为疗法在改善帕金森病膀胱过度活动症症状方面不劣于索利那新。
  • 药物组口干和跌倒报告频率高于行为疗法组。
  • 行为疗法可作为帕金森病泌尿症状的初始治疗选择。

核心结论

  • 行为疗法在改善帕金森病膀胱过度活动症症状方面不劣于索利那新药物治疗。

研究设计与样本

  • 2018至2023年在美国4个退伍军人事务医疗系统开展的12周随机非劣效性试验,共随机77例帕金森病患者(行为组36例,药物组41例)。

主要发现

  • 药物组口干和跌倒报告频率高于行为组。

关键数值与推荐

  • 纳入标准为运动障碍神经科医生诊断帕金森病、ICIQ-OAB症状评分≥7分(范围0-16)且MOCA评分≥18分(范围0-30)。
  • 主要结局为12周ICIQ-OAB评分,非劣效界值为15%。
  • 行为疗法由执业护士实施,包括盆底肌训练和尿急抑制策略;索利那新起始5 mg每日,必要时滴定至10 mg每日。

临床怎么用

  • 帕金森病膀胱过度活动症患者可考虑将盆底肌训练为基础的行为疗法作为初始治疗选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Overactive bladder (OAB) symptoms in Parkinson disease (PD) are burdensome, and the adverse effects of drug treatment can worsen PD-associated morbidity. Drug adverse effects are avoided with pelvic floor muscle exercise-based behavioral therapy. OBJECTIVE: To assess the noninferiority of behavioral compared with solifenacin drug therapy for OAB symptoms in persons with PD. DESIGN, SETTING, AND PARTICIPANTS: This 12-week randomized noninferiority trial of behavioral therapy compared with solifenacin was conducted between 2018 and 2023 within 4 US Veterans Affairs health care systems. Eligible participants were diagnosed with PD by a movement disorder neurologist and had an International Consultation on Incontinence Questionnaire OAB module (ICIQ-OAB) symptom score of 7 or higher (range, 0-16; higher score indicates worse symptoms) and Montreal Cognitive Assessment (MOCA) score of 18 or higher (range, 0-30). Participants were randomized 1:1 after stratification by sex, recruitment site, OAB severity, and PD motor symptom severity. Analyses were conducted from October 2023 to April 2024. INTERVENTIONS: Behavioral therapy was implemented by a nurse practitioner and included pelvic floor muscle training and urge suppression strategies. Solifenacin therapy started at 5 mg daily, with titration to 10 mg daily if needed. MAIN OUTCOME AND MEASURES: The primary outcome was the 12-week ICIQ-OAB score across groups within a 15% noninferiority margin. Adverse events were assessed every 2 weeks for 8 weeks and again at 12 weeks. RESULTS: A total of 77 persons with PD (65 [84%] male; mean [SD] age, 71.3 [8.9] years; mean [SD] years with PD, 6.6 [5.8]) were randomized to behavioral (n = 36) or drug therapy (n = 41). Seventy-three participants completed the study (4 dropped out in drug group). Baseline characteristics were balanced across groups, including MOCA score (mean [SD], drug, 23.9 [3.1]; behavioral, 24.8 [3.3]) and ICIQ-OAB score (mean [SD], drug, 9.1 [1.7]; behavioral, 8.5 [1.4]). At 12 weeks postrandomization, ICIQ-OAB scores across groups indicated clinically significant improvement and were within the a priori noninferiority margin of 15% (mean [SD] score, drug, 5.8 [2.4]; behavioral, 5.5 [2.0]; P = .02). Dry mouth and falls were reported more frequently in the drug compared with the behavioral group. CONCLUSIONS AND RELEVANCE: Results of this randomized noninferiority trial suggest that behavioral therapy is noninferior to drug therapy in improving OAB symptoms in PD. These findings may inform clinical guidelines for urinary symptoms in PD to consider behavioral therapy as an initial treatment option. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03149809.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Vaughan CP, Morley JF, Lehosit J, et al. Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease: A Randomized Noninferiority Trial. JAMA Neurol. 2025. PMID: 40658410. doi:10.1001/jamaneurol.2025.1904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。